BiomX Inc
8.11 %
47.06 %
Yet to be announced
Company Overview
BiomX Inc. is a clinical-stage microbiome company developing both natural and engineered phage therapies that target specific pathogenic bacteria. The company focuses on developing treatments for diseases related to microbiome dysfunction, including inflammatory bowel disease, primary sclerosing cholangitis, colorectal cancer, atopic dermatitis, and acne.
The company's primary business model involves research, development, and potential commercialization of phage-based therapeutic products. Their technology platform enables them to develop precision phage cocktails designed to target and destroy harmful bacteria that affect human health.
Revenue Sources
PassBiomX is a clinical-stage biotechnology company focused on developing phage therapies. The company's revenue primarily comes from research and development activities and potential therapeutic products. None of their current or planned revenue streams involve haram products or services.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
The company is still in its pre-revenue research and development phase, typical for clinical-stage biotech companies. As such, the interest ratio checks are not applicable at this stage of the company's development.
Operational Ethics
PassBased on available information from SEC filings and company materials, BiomX operates primarily in the United States. There is no evidence of current material associations with entities involved in human rights violations such as the state of Israel or the Chinese Communist Party.
Comments